Mar 23 2008
NicOx’ Naproxcinod Shows Robust Blood Pressure Results In Phase 3 Pooled Analysis
generic acomplia online buy NicOx S.A. (NYSE Euronext Paris: COX) announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (pGeneric levitra pills no prescription | Generic diflucan pills no prescription | Buy generic cialis